Howard Mayer
Director/Board Member bei PEPGEN INC.
Profil
Dr. Howard Mayer, MD, ist Executive Vice President-Research & Development bei Ipsen SA, ein unabhängiger Direktor bei Entasis Therapeutics Holdings, Inc. und Executive VP, Head-Research & Development bei Ipsen Pharmaceuticals, Inc. Er ist Mitglied des Board of Directors von Adagio Therapeutics, Inc. und Entasis Therapeutics Holdings, Inc. sowie der Melmark Charitable Foundation. Dr. Mayer war zuvor als unabhängiger Direktor bei Genocea Biosciences, Inc. beschäftigt, als Chief Medical Officer, Senior VP, Head-R&D bei Shire Plc, als Chief Medical Officer bei EMD Serono, Inc, als Head-Clinical Development & Medical Affairs bei Pfizer Inc, als Director-Infectious Diseases Clinical Research bei Bristol Myers Squibb Co. und als Head-Rare Disease Business Unit, R&D bei Takeda Pharmaceuticals U.S.A., Inc. Außerdem war er Vorstandsmitglied bei Autism Speaks, Inc. Er erhielt seinen Undergraduate-Abschluss von der University of Pennsylvania und seinen Doktortitel vom Albert Einstein College of Medicine, Inc.
Aktive Positionen von Howard Mayer
| Unternehmen | Position | Beginn |
|---|---|---|
| PEPGEN INC. | Director/Board Member | 15.11.2023 |
Melmark Charitable Foundation
 Melmark Charitable Foundation Investment Trusts/Mutual FundsMiscellaneous Melmark Charitable Foundation manages and coordinates all fundraising efforts throughout the Melmark organization. | Director/Board Member | 01.01.2016 |
Autism Speaks, Inc.
 Autism Speaks, Inc. Miscellaneous Commercial ServicesCommercial Services Autism Speaks, Inc. is an organization dedicated to advocating for individuals with autism spectrum disorder and their families. The non-profit company is based in New York, NY. The company aims to increase understanding and acceptance of people with autism and advance research into better interventions for autism spectrum disorder and related conditions. The company was founded by Robert C. Wright and Keith Andrew Wargo has been the CEO of the company since 2021. | Director/Board Member | 01.01.2011 |
Ipsen Pharmaceuticals, Inc.
 Ipsen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ipsen Pharmaceuticals, Inc. provides pharmaceutical products. The private company is based in Morristown, NJ. | Chief Tech/Sci/R&D Officer | 01.01.2019 |
Ehemalige bekannte Positionen von Howard Mayer
| Unternehmen | Position | Ende |
|---|---|---|
| IPSEN | Chief Tech/Sci/R&D Officer | 22.09.2023 |
| Ipsen Biopharmaceuticals, Inc. | Chief Tech/Sci/R&D Officer | 01.09.2023 |
| ENTASIS THERAPEUTICS HOLDINGS INC. | Director/Board Member | 01.07.2022 |
| INVIVYD, INC. | Director/Board Member | 24.06.2022 |
| GENOCEA BIOSCIENCES, INC. | Director/Board Member | 03.08.2020 |
Ausbildung von Howard Mayer
| University of Pennsylvania | Undergraduate Degree |
| Albert Einstein College of Medicine, Inc. | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 6 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| PFIZER, INC. | Health Technology |
| IPSEN | Health Technology |
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| INVIVYD, INC. | Health Technology |
| PEPGEN INC. | Health Technology |
| Private Unternehmen | 8 |
|---|---|
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Health Technology |
Autism Speaks, Inc.
Autism Speaks, Inc. Miscellaneous Commercial ServicesCommercial Services Autism Speaks, Inc. is an organization dedicated to advocating for individuals with autism spectrum disorder and their families. The non-profit company is based in New York, NY. The company aims to increase understanding and acceptance of people with autism and advance research into better interventions for autism spectrum disorder and related conditions. The company was founded by Robert C. Wright and Keith Andrew Wargo has been the CEO of the company since 2021. | Commercial Services |
Takeda Pharmaceuticals U.S.A., Inc.
 Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Health Technology |
Shire Pharmaceuticals, Inc.
 Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
Ipsen Pharmaceuticals, Inc.
Ipsen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ipsen Pharmaceuticals, Inc. provides pharmaceutical products. The private company is based in Morristown, NJ. | Health Technology |
| Ipsen Biopharmaceuticals, Inc. | |
Melmark Charitable Foundation
Melmark Charitable Foundation Investment Trusts/Mutual FundsMiscellaneous Melmark Charitable Foundation manages and coordinates all fundraising efforts throughout the Melmark organization. | Miscellaneous |
Entasis Therapeutics Holdings, Inc.
 Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
